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p53 is the most frequently mutated tumour suppressor gene identi-
fied to date (Hollstein et al, 1991), and Kaghad et al (1997)
reported a novel gene, termed p73, that encodes a nuclear protein
sharing significant sequence homology with p53, especially in the
domains of transcriptional activation, DNA-binding and oligomer-
ization. p73 activates the transcription of p21waf1/cip1, inhibits cell
growth, and induces apoptosis (Jost et al, 1997); however, unlike
p53, p73 is not induced by exposure of cells to DNA-damaging
agents such as UV irradiation (Kaghad et al, 1997). 
The chromosomal localization of p73 is proximal to marker
D1S468 and distal to marker D1S47, at 1p36.33–p36.32 (Liu et al,
2000). This region is frequently deleted in a variety of human
tumours (Mitelman et al, 1997). We previously reported 1p allelic
deletions in about 30% of brain tumours (Bello et al, 1995a), with
higher frequencies of loss found in oligodendrolgiomas and
meningiomas, and a lesser degree in neurofibrosarcomas, schwan-
nomas and primary lymphomas. Most of these tumour types
display a low frequency of p53 abnormalities, suggesting that
other molecular carcinogenic pathways may participate during
their progression (Ohgaki et al, 1991). 
Human carcinogenesis is believed to be a multistage process
involving somatic activation of protooncogenes and inactivation
of tumour suppressor genes or DNA repair genes. In brain
tumours, some of these genetic alterations have been outlined for
astrocytic neoplasms (von Deimling et al, 1995), and recent data
on molecular progression of meningioma and oligodendroglioma
have emerged (Reifemberger et al, 1994; Bello et al, 1995b; Kraus
et al, 1995; Simon et al, 1995; Leone et al, 1999; Smith et al,
1999). Several 1p candidate tumour suppressor genes have been
analysed for inactivating mutations in oligodendrogliomas and
meningiomas, including hRAD54 and CDKN2C genes. There is
nonetheless insufficient evidence to consider these genes as candi-
date tumour suppressor genes in these nonastrocytic neoplasms
(Huseman et al, 1999; Mendiola et al, 1999; Bello et al, 2000b). 
To evaluate possible p73 involvement in the pathogenesis of
nonastrocytic brain tumours, we analysed 65 tumour samples for
mutations of the p73 gene, and loss of heterozygosity at the 1p36
region. Contrary to our predictions, we found that the p73 muta-
tion was infrequent in these tumour types. 
MATERIALS AND METHODS 
Tissue samples and DNA preparation 
Normal tissues and tumour biopsies from 65 patients with nonas-
trocytic brain tumours were collected during surgical procedures
and frozen immediately at –80˚C until use. All samples were clas-
sified by histologic examination and graded according to WHO
guidelines (Kleihues et al, 1993). The group of 65 tumours
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consisted of 26 oligodendrogliomas, 4 ependymomas, 5 medullo-
blastomas, 10 meningiomas, 2 meningeal haemangiopericytomas,
3 primary lymphomas, 2 neurofibrosarcomas, 8 schwannomas and
5 metastatic tumours to the brain. The tumour cell content was
estimated by histologic examination to be approximately 75–80%. 
DNA was prepared from frozen tissues and blood samples using
standard methods, as described previously (Rey et al, 1992). 
Loss of heterozygosity at 1p36–p35
To verify LOH at 1p36–p35, restriction fragment length polymor-
phism (RFLP) and microsatellite analyses were performed using the
methods of Leone et al (1999), and the allelic constitution of the
following 1p markers was determined: D1Z2, D1S80, D1S76, and
D1S77, located at 1p36.33; D1S468, and D1S234, at 1p36.32;
D1S199, at 1p36.12, and D1S214, at 1p35.3. The plasmids and/or
oligonucleotide primers used to detect these markers have been
described previously (Bello et al, 2000a), and were obtained from the
American Type Culture Collection (Manassas, VA) or GENSET, SA
(France). Restriction endonuclease digestion, agarose gel elec-
trophoresis, southern blotting, 32P-labelling of DNA probes,
hybridization and autoradiography were performed as described
(Rey et al, 1992). Cytosine adenine repeat polymorphisms were
analysed using polymerase chain reaction in standard conditions; the
alleles were resolved in 6% polyacrylamide gels and then silver
stained (Bender et al, 1994). Scanning densitometry was performed
to determine the allelic status of markers studied by RFLP/autoradi-
ography or PCR/SSCP/silver stain as described in detail elsewhere
(Bello et al, 2000a). Loss of heterozygosity was defined as greater
than 75% reduction in band intensity relative to the non-tumour
control. 
SSCP analysis and direct sequencing of p73 gene 
Genomic PCR amplification of coding exons 2–14 of the p73 gene
and their splice site junction sequences were performed using the
primers described by Yoshikawa et al (1999) (purchased from
GENSET). PCR conditions were 35 cycles of 94˚C for 30 s,
55–68˚C for 30 s, and 72˚C for 90 s, with a final extension of 7
min at 72˚C. The PCR products were loaded onto 6–12% nonde-
naturing polyacrylamide gels (with or without 10% glycerol),
electrophoresed and silver stained as above. Samples displaying
an altered PCR-SSCP pattern were reamplified by PCR, with the
same set of primers, and the PCR products were sequenced using
the ABI PRISM Big Dye Terminator Cycle Sequencing Kit
(Perkin Elmer, Alameda, CA). Each amplicon was sequenced
bidirectionally. 
RESULTS 
Allelic loss at the p73 region (1p36.33–p36.32) could be un-
ambiguously determined in 33 of the 65 tumour samples (50%),
corresponding to 22 oligodendrogliomas, 1 ependymoma, 4
meningiomas, 1 lymphoma, 1 neurofibrosarcoma, 2 schwannomas
and 2 metastatic tumours to the brain. Detailed data on the allelic
constitution have been partially reported previously (Bello et al,
1995a, and unpublished data). 
The genomic region from exons 2 to 14, which cover the entire
coding frame of p73, was searched for mutations in all 65 tumours.
We found a single tumour (primary lymphoma) characterised by a
missense mutation, a G-to-A change at nucleotide 871 (exon 8), that
is, a Glu291Lys (GAG to AAG) change (Figure 1). 2 silent muta-
tions (or polymorphisms) were identified in both samples corre-
sponding to grade II and grade III of an oligodendroglioma patient
(case K-9). The first was a G-to-A transition at nucleotide 438
(exon 5), which does not result in aminoacid change (CCG to CCA;
no change Pro 146). The second exon 5 polymorphism detected in
both samples was a C-to-T change at nucleotide 612, with no
change of Asn 204. Both exon 5 polymorphic variations were also
detected in an ependymoma (case K-30). 5 additional tumours
displayed nucleotide changes occurring in the introns. One delG at
the downstream region of exon 3 (+12) position was identified in 2
oligodendrogliomas, 1 ependymoma and 1 meningioma. Finally, a
C-to-T change at the exon 2(+10) position was identified in one
brain metastatic lesion from a lung carcinoma. A summary of the
nucleotide changes detected in all 9 tumours is shown in Table 1. 
Allele loss at the 1p36 region was identified in 4 tumours with
p73 sequence changes; these corresponded to 3 samples of oligo-
dendroglioma and to the brain metastatic lesion from a lung carci-
noma. Allelic retention was evidenced in the case with missense
mutation (tumour K-42). 
DISCUSSION 
Chromosomal region 1p36 is frequently deleted in human cancer
(Mitelman et al, 1997), and considered to harbour up to 3 tumour
suppressor genes relevant to the carcinogenesis of a variety of
neoplasms (Vergsteeg et al, 1995). We previously performed dele-
tion mapping analysis of 1p in a broad series of 236 tumours of the
nervous system, including all major histologic subtypes (Bello 
et al, 1995a), and determined that an average of 30% of cases
displayed allelic losses at that chromosomal region. We then
performed high-resolution deletion mapping analyses (composite
average resolution of 4.04 cM) in nonastrocytic brain tumours and
allelic imbalance at 1p36 was identified in 28% of meningiomas
and 74% of tumours with a major oligodendroglial component
(Bello et al, 2000a, b). At a lower frequency, 1p36 deletions were
Figure 1 Exon 8 missense mutation at position 871 of p73 gene (G-to-A:
Glu291Lys change). To the left is shown the SSCP analysis corresponding to
the constitutional (L) and tumoural (T) DNAs of case K-42, and to a normal
control DNA (C). Forward (F) and reverse (R) sequences corresponding to
the tumour DNA show the nucleotide change 206 ME Alonso et al
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also identified in schwannomas, neurofibrosarcomas and primary
lymphomas (Bello et al, 1995a, and unpublished data), and similar
deletions are evidenced in the present report. These data concur
with previous findings in other tumour types, prompting us to
analyse molecular abnormalities of candidate genes at 1p36. 
p73, a p53-related gene, has been located in this critical region
(Kaghad et al, 1997; Liu et al, 2000) and may be the putative
tumour suppressor gene involved in carcinogenesis in a variety of
neoplasms, including nonastrocytic brain tumours. In this study we
screened 65 nonastrocytic brain tumours for p73 gene mutations,
but identified only a single case with a missense mutation,
Glu291Lys in a primary lymphoma which nevertheless retained
the intact allele, shown by the retention of heterozygosity at the
1p36 region. We also detected 8 additional cases displaying poly-
morphic changes, as they were also present in the corresponding
constitutional DNA, but not all evidenced LOH at 1p36. 
Taken together, our findings do not support a major role for p73 as
a tumour suppressor gene in nonastrocytic brain tumours. Similar
findings were previously reported for oligodendrogliomas (Mai et al,
1998; Tsujimoto et al, 2000), as several polymorphic nucleotide vari-
ations, but no somatic mutations that caused amino acid changes
were detected. High resolution deletion mapping analysis of 1p in
meningioma and oligodendroglioma has demonstrated that more
than one tumour suppressor gene from this genomic region might be
involved. We previously performed mutational studies of the
hRAD54 gene (located at 1p32) in those nonastrocytic brain tumours,
but no mutational changes were detected (Mendiola et al, 1999; Bello
et al, 2000b). Abnormalities of the CDKN2C gene are likewise rarely
found in oligodendrogliomas with 1p deletion (Huseman et al, 1999)
and, the target gene of these highly frequent 1p deletions, character-
istic of the brain neoplasms, thus remains to be identified. As far as
we know, mutational analysis of the p73 gene has been performed in
several human cancers (Levrero et al, 2000), but no data are available
for the other nonastrocytic brain tumour types we studied. In accor-
dance with our findings, mutations of the gene are rarely found. In
this respect, van Gele et al (2000) described the finding of a sporadic
p73 NH2-terminal located missense mutation in one of 10 Merkel cell
carcinomas studied. Ichimiya et al (1999) found one somatic and one
germ-line mutation in a series of 140 neuroblastomas, and Han et al
(1999) described a somatic missense mutation at codon 269 in one
breast cancer. Peng et al (2000) identified a 5-nucleotide deletion in
the DNA-binding domain of the gene in one hepatocellular carci-
noma. This change resulted in a reading frame early truncation of p73
protein, and a predicted loss of biological function. The findings in
our tumour series concur with those data in that a low incidence of
p73 mutation was detected. Only one tumour sample displayed an
amino acid substitution, while most SSCP variations detected corre-
sponded to silent polymorphisms, and less frequently to changes in
the intronic sequences. These findings confirm previous results
suggesting that instability in the splicing of p73 exons occurs in
cancer cells, but its role is unclear (Levrero et al, 1999). 
The change we have found (Glu291Lys) is located within the
DNA-binding domain (DBD) of p73, and might represent impor-
tant implications for cancer development. A high level of
homology is reached in the p73/p63/p53 DBD (63% identity)
suggesting that these proteins might bind to identical DNA
sequences and thus transactivate the same promoters (Yang et al,
1998; Levrero et al, 2000). Homologous Glu-Lys mutations have
been described at codon 271 of p53 in astrocytomas (Mashiyama
et al, 1991), and some truncated forms of p73/p63, as well as
changes at p73 codon 293 might act as dominant negative factors
in respect to transactivation by p53 and p73 alpha (Yang et al,
1998; Fillipovich et al, 2001). Accordingly, the mutation
Glu291Lys we detected might inactivate p73, and might be of
special interest regarding lymphoma development. In this respect,
allelic loss at p73 has been described in non-Hodgkin lymphomas
(Herranz et al, 2000), and stimulation of a T lymphoblastoid cell
line or human lymphocytes with phytohaemagglutinin has been
shown to increase p73 expression (De Laurenzi et al, 1999).
Recently, Lissy et al (2000) demonstrated that p73 is a specific
mediator of T-cell receptor activation-induced cell death, and
methylation changes of p73 that might suppress expression of the
gene are common in T-cell lymphomas, acute lymphoblastic
leukaemia or B-cell-derived Burkitt’s lymphoma (Corn et al,
1999; Kawano et al, 1999). The loss of p73, thus, could lead
to defects in cell-cycle regulation or confer selective growth
advantages. 
p73 was originally reported to be expressed monoallelically
(Kaghad et al, 1997), but there have been controversial reports on
the allelic expression imbalance of this gene (Nomoto et al, 1998;
Takahashi et al, 1998; Kawano et al, 1999; Yokozaki et al, 2000).
Whether loss of genomic imprinting is a tumorigenic mechanism
for p73, therefore remains controversial. Although both p53 and
p73 may function similarly, it has been suggested that p73 is
involved primarily in development (Yang et al, 2000), and is active
in response to some types of DNA damage (reviewed by White
and Prives, 1999). It was recently suggested that altered p73
expression rather than a loss of function may be involved in
tumorigenesis (Levrero et al, 2000). 
In conclusion, the present study clearly demonstrates frequent
allelic loss at 1p36, where the p73 gene is located, in nonastrocytic
brain tumours. We describe the finding of a p73 missense mutation
Table 1 Mutation and polymorphisms identified in the p73 gene in nonastrocytic brain tumours 
Sample Tumour type Exon/intron Nucleotide change AA change LOH 1p36 
K-9 T1 O 5 438G>A/612C>T Pro146Pro/Asn204Asn + 
K-9 T2 AO 5 438G>A/612C>T Pro146Pro/Asn204Asn + 
K-13 O 3/+12 delG – + 
K-15 O 3/+12 delG – – 
K- 30 E 5 438G>A/612C>T Pro146Pro/Asn204Asn – 
K-32 E 3/+12 delG – – 
K-42 L 8 871G>A Glu291Lys – 
K-43 M 3/+12 delG – – 
K-59 Met-LungCa 2/+10 C>T – + 
Tumour type: O = oligodendroglioma; AO = anaplastic oligodendroglioma; E = ependymoma; L = primary brain lymphoma; 
M = meningioma; Met-Lung Ca = lung carcinoma metastatic to the brain.   that might inactivate the gene, in a primary intracranial lymphoma,
together with the identification of 3 previously reported poly-
morphic changes. Nevertheless, p73 does not seem to behave as a
classical ‘two-hit’ tumour suppressor gene in nonastrocytic brain
tumours, as our study provides evidence that mutation of this gene
is unlikely to play a major role in the pathogenesis of these
nervous system tumours, other than brain primary lymphomas.
The high incidence of 1p36 deletions clearly provides evidence for
a tumour suppressor gene located here, whose inactivation would
be a critical step in promoting tumour growth in these neoplasms. 
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